國立高雄大學圖資館 |

Language: English

Back

Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.
Author:	Huang, Zhouyang.
Published:	Ann Arbor : ProQuest Dissertations & Theses, 2023
Description:	244 p.
Notes:	Source: Dissertations Abstracts International, Volume: 85-03, Section: B.
Notes:	Advisor: Wilson, Justin.
Contained By:	Dissertations Abstracts International85-03B.
Subject:	Inorganic chemistry.
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30527302
ISBN:	9798380314169

Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.
Huang, Zhouyang.

Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates. - Ann Arbor : ProQuest Dissertations & Theses, 2023 - 244 p.

Source: Dissertations Abstracts International, Volume: 85-03, Section: B.

Thesis (Ph.D.)--Cornell University, 2023.

This item must not be sold to any third party vendors.

The clinical success of cisplatin and other platinum-based chemotherapeutics has inspired extensive research efforts to develop alternative metallodrugs with improved pharmacological properties. The first section of this dissertation focuses on design of novel metallodrugs for cytotoxic anticancer applications. Recently, rhenium(I) tricarbonyl complexes have attracted significant attention as novel anticancer agents, because their mechanisms of action are distinct from the DNA-binding pathways that are operative for platinum(II) complexes. Chapter 1 is a comprehensive review of the recent developments of multimetallic rhenium(I) tricarbonyl complexes for therapeutic and diagnostic applications. Chapter 2 describes the development of the first Pt(IV)Re(I) molecular conjugates as photoactivated anticancer agents.The second section of this dissertation explores the use of metal complexes as cytoprotective agents targeting the mitochondrial calcium uniporter (MCU), a transmembrane protein that is responsible for shuttling cytosolic Ca2+ into mitochondria. Dysregulation of the MCU can trigger an overload of mitochondrial Ca2+, which is implicated in the progression of cardiovascular and neurodegenerative diseases. As such, the chemical inhibition of MCU represents a promising therapeutic strategy. Chapter 3 summarizes recent advances in metal-based MCU inhibitors and highlights a diruthenium coordination complex, Ru265, as the state-of-the-art MCU inhibitor due to its excellent potency, selectivity, and cellular permeability. Chapter 3 also outlines the structure-activity relationship of Ru265-based MCU inhibitors. Chapter 4 describes a ferrocene-functionalized analogue of Ru265 and demonstrates that the cellular permeability of this class of MCU inhibitors can be rationally improved through ligand functionalization. Finally, Chapter 5 details the development of the first fluorogenic MCU inhibitor, a coumarin-functionalized analogue of Ru265.Collectively, these results demonstrate the potential of metal complexes for cytotoxic and cytoprotective applications and provide strategies for the rational design of metallodrug candidates.

ISBN: 9798380314169Subjects--Topical Terms:

708705
Inorganic chemistry.
Subjects--Index Terms:

Rhenium

Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.
LDR:03323nmm a2200385 4500 001 655797
005 20240414211933.5
006 m o d
007 cr#unu||||||||
008 240620s2023 ||||||||||||||||| ||eng d
020 $a 9798380314169
035 $a (MiAaPQ)AAI30527302
035 $a AAI30527302
040 $a MiAaPQ $c MiAaPQ
100 1 $a Huang, Zhouyang. $0 (orcid)0000-0003-0335-2020 $3 966885
245 1 0 $a Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2023
300 $a 244 p.
500 $a Source: Dissertations Abstracts International, Volume: 85-03, Section: B.
500 $a Advisor: Wilson, Justin.
502 $a Thesis (Ph.D.)--Cornell University, 2023.
506 $a This item must not be sold to any third party vendors.
520 $a The clinical success of cisplatin and other platinum-based chemotherapeutics has inspired extensive research efforts to develop alternative metallodrugs with improved pharmacological properties. The first section of this dissertation focuses on design of novel metallodrugs for cytotoxic anticancer applications. Recently, rhenium(I) tricarbonyl complexes have attracted significant attention as novel anticancer agents, because their mechanisms of action are distinct from the DNA-binding pathways that are operative for platinum(II) complexes. Chapter 1 is a comprehensive review of the recent developments of multimetallic rhenium(I) tricarbonyl complexes for therapeutic and diagnostic applications. Chapter 2 describes the development of the first Pt(IV)Re(I) molecular conjugates as photoactivated anticancer agents.The second section of this dissertation explores the use of metal complexes as cytoprotective agents targeting the mitochondrial calcium uniporter (MCU), a transmembrane protein that is responsible for shuttling cytosolic Ca2+ into mitochondria. Dysregulation of the MCU can trigger an overload of mitochondrial Ca2+, which is implicated in the progression of cardiovascular and neurodegenerative diseases. As such, the chemical inhibition of MCU represents a promising therapeutic strategy. Chapter 3 summarizes recent advances in metal-based MCU inhibitors and highlights a diruthenium coordination complex, Ru265, as the state-of-the-art MCU inhibitor due to its excellent potency, selectivity, and cellular permeability. Chapter 3 also outlines the structure-activity relationship of Ru265-based MCU inhibitors. Chapter 4 describes a ferrocene-functionalized analogue of Ru265 and demonstrates that the cellular permeability of this class of MCU inhibitors can be rationally improved through ligand functionalization. Finally, Chapter 5 details the development of the first fluorogenic MCU inhibitor, a coumarin-functionalized analogue of Ru265.Collectively, these results demonstrate the potential of metal complexes for cytotoxic and cytoprotective applications and provide strategies for the rational design of metallodrug candidates.
590 $a School code: 0058.
650 4 $a Inorganic chemistry. $3 708705
650 4 $a Chemistry. $3 188628
650 4 $a Biochemistry. $3 188609
653 $a Rhenium
653 $a Platinum
653 $a Ruthenium
653 $a Metallodrug candidates
690 $a 0488
690 $a 0487
690 $a 0485
710 2 $a Cornell University. $b Chemistry and Chemical Biology. $3 966886
773 0 $t Dissertations Abstracts International $g 85-03B.
790 $a 0058
791 $a Ph.D.
792 $a 2023
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30527302